Latest Conference Articles

Researchers presented findings in conjunction with the Society of Gynecologic Oncology 2020 Annual Meeting on Women’s Cancer on the phase 3 VELIA trial studying the safety of veliparib.

The CLIO trial evaluated olaparib single-agent therapy versus standard-of-care chemotherapy in platinum-sensitive recurrent epithelial ovarian cancer.

The objective of the study was to analyze whether USC would be uniquely sensitive to further interference of cell cycle regulation by Wee1 inhibition.

The objective of the study was to find whether niraparib improves PFS in patients with newly diagnosed advanced ovarian cancer after first-line (1L) platinum-based chemotherapy (CT).

XMT-1536, a first-in-class antibody-drug conjugate NaPi2B was well tolerated with no dose-limiting toxicities in patients with ovarian cancer and non-small cell lung cancer (NSCLC).

However, the magnitude of the progression-free survival (PFS) benefit is greatest when surgery achieved complete surgical debulking, specifically in the upfront setting.

The objective of the study was to analyze whether niraparib improves PFS in patients with newly diagnosed advanced ovarian cancer after response to first-line platinum-based chemotherapy.

Front-line use of vigil immunotherapy as maintenance in stage 3-4 ovarian cancer was well tolerated and demonstrated relapse-free survival clinical benefit.

Study findings suggest that veliparib added to carboplatin and paclitaxel during combination phase may provide anti-tumor activity versus carboplatin and paclitaxel alone.

Homologous recombination deficiency is not predictive of patient outcomes for veliparib-throughout versus control in patients with BRAC wildtype ovarian carcinomas.

Kirollos Hanna, PharmD, BCPS, BCOP, explains antibody drug conjugates and their method of action. This video was filmed at the Hematology/Oncology Pharmacists Association 2020 Meeting in Tampa, Florida.

Lesbian, gay, bisexual, transgender, and queer (LGBTQ) patients with cancer face specific barriers when seeking medical care, but pharmacists and other medical professionals can take specific steps to reduce the gaps in care.

Pharmacy Times will be on-site next week to provide coverage of the sessions, recaps of the panel discussions, and interviews with the experts.

Patients with ulcerative colitis have an increased risk of developing colorectal cancer (CRC), are diagnosed with less advanced CRC, and are at increased risk of death from CRC.

Patients diagnosed with Crohn disease and colorectal cancer (CRC) have a higher rate of mortality than patients without Crohn disease who are also diagnosed with CRC.

The discharge pharmacy service at West Virginia University (WVU) Medicine in Morgantown is intended to be a ‘patient first’ program that ensures patients receive the medications prescribed in hand, and that they remain adherent through medication counseling and followup.

Margetuximab plus chemotherapy showed positive results in a second pre-specified interim overall survival analysis for the phase 3 SOPHIA study.

Todd Brothers, PharmD, BCCCP, BCPS, clinical assistant professor, University of Rhode Island, discusses what patients should know about medications that cause hyperkalemia. This video was filmed at the ASHP (American Society of Health-System Pharmacists) 54th Clinical Meeting & Exhibition in Las Vegas, Nevada.

Because of the vulnerabilities of CDK4/6i-resistant tumors, researchers believe that it is imperative to improve the survival of this group of patients.

Since 2004, the FDA has approved different treatments for advanced prostate cancer, adding almost 2-3 indications per year for the past 15 years.

By entering clinical and disease characteristics into a learning algorithm, researchers were able to create an efficacy prediction for CDK inhibitors.

Abemaciclib is a potent oral cyclin-dependent kinase 4/6 inhibitor that has previously demonstrated statistically significant improvement in PFS and ORR in combination with endocrine therapy.

Rita Nanda, MD, explains how researchers are aiming to make immunologically silent tumors more inflamed. This video was filmed at the 2019 San Antonio Breast Cancer Symposium.

Jaclyn Harth, PharmD, clinical assistant professor, Fairleigh Dickinson School of Pharmacy, discusses 1 of the clinical pearls for potassium binders. This video was filmed at the ASHP (American Society of Health-System Pharmacists) 54th Clinical Meeting & Exhibition in Las Vegas, Nevada.

ASHP’s annual Pharmacy Forecast is designed to help advance pharmacy practice leadership, and to provide insight into the forecasted trends.

Banu Arun, MD, explains the potential risks of passive genetic counseling via videos or at-home tests. This video was filmed December 12 at the 2019 San Antonio Breast Cancer Symposium.

Megan Maroney, PharmD, BCPP, clinical associate professor, Ernest Mario School of Pharmacy at Rutgers, the State University of New Jersey; clinical psychiatric pharmacist, Monmouth Medical Center, Long Branch, NJ, discusses the higher risk for potential adverse effects of suicidal ideation and behavior, and depression in younger patients.

Jaclyn Harth, clinical assistant professor, Fairleigh Dickinson School of Pharmacy, explains the dietary considerations for patients with chronic hyperkalemia. This video was filmed at the ASHP (American Society of Health-System Pharmacists) 54th Clinical Meeting & Exhibition in Las Vegas, Nevada.

Advanced pharmacy technician roles are on the rise, with new certification programs available for students to utilize, according to a session at the ASHP (American Society of Health-System Pharmacists) 54th Midyear Clinical Meeting & Exhibition in Las Vegas.

Todd Brothers, clinical assistant professor, University of Rhode Island, explains how to address hyperkalemia assessed in patients. This video was filmed at the ASHP (American Society of Health-System Pharmacists) 54th Clinical Meeting & Exhibition in Las Vegas, Nevada.